
Exagen
Total Raised
$156.13MInvestors Count
10Deal Terms
4Funding, Valuation & Revenue
34 Fundings
Exagen has raised $156.13M over 34 rounds.
Exagen's latest funding round was a PIPE for $60.1M on March 21, 2021.
Exagen's valuation in September 2019 was $157.27M.
Exagen's 2020 revenue was $41.98M. Exagen's most recent revenue is from 2020.
Sign up for a free demo to see revenue data from 2021, 2020 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
3/21/2021 | PIPE | $60.1M | Undisclosed Investors | 2 | ||
9/19/2019 | IPO | $50.4M | $157.27M | 1 | ||
2/1/2019 | Series G | $6.59M | $41.98M FY 2020 | 1 | ||
9/11/2017 | Debt - XVII | |||||
5/18/2017 | Unattributed |
Date | 3/21/2021 | 9/19/2019 | 2/1/2019 | 9/11/2017 | 5/18/2017 |
|---|---|---|---|---|---|
Round | PIPE | IPO | Series G | Debt - XVII | Unattributed |
Amount | $60.1M | $50.4M | $6.59M | ||
Investors | Undisclosed Investors | ||||
Valuation | $157.27M | ||||
Revenue | $41.98M FY 2020 | ||||
Sources | 2 | 1 | 1 |
Exagen Deal Terms
4 Deal Terms
Exagen's deal structure is available for 4 funding rounds, including their IPO from September 19, 2019.
Round | IPO | Series B - II | Series B | Series A |
|---|---|---|---|---|
Funding Date | ||||
Pre-Money Valuation | ||||
Post-Money Valuation | ||||
Amount Raised | ||||
Shares Authorized | ||||
Issuance Price | ||||
Dividend Rate | ||||
Liquidation Preferences | ||||
Liquidation Price | ||||
Participation | ||||
Conversion Price | ||||
Anti Dilution | ||||
General Voting | ||||
Board Voting | ||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series B - II | |||||||||||||||
Series B | |||||||||||||||
Series A |
Exagen Investors
10 Investors
Exagen has 10 investors. Tullis Health Investors invested in Exagen's Series G funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
1/5/2004 | 2/1/2019 | 12 Series A, Series B (2005), Series B - II (2006), Debt (2007), Debt - II (2008), Series C (2009), Series C - II (2011), Series C - III (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series G (2019) | Thomas Dickerson | Private Equity | Connecticut | |
5/6/2009 | 2/1/2019 | 11 Series C, Series C - II (2011), Series C - III (2011), Series C - IV (2011), Debt - III (2011), Series D (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series F (2016), Series G (2019) | Investment Bank | New Mexico | ||
5/6/2009 | 2/1/2019 | 11 Series C, Series C - II (2011), Series C - III (2011), Series C - IV (2011), Debt - III (2011), Series D (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series F (2016), Series G (2019) | Venture Capital | New Mexico | ||
Debt & Specialty Finance | New York | |||||
Debt & Specialty Finance | Texas |
First funding | 1/5/2004 | 5/6/2009 | 5/6/2009 | ||
|---|---|---|---|---|---|
Last Funding | 2/1/2019 | 2/1/2019 | 2/1/2019 | ||
Investor | |||||
Rounds | 12 Series A, Series B (2005), Series B - II (2006), Debt (2007), Debt - II (2008), Series C (2009), Series C - II (2011), Series C - III (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series G (2019) | 11 Series C, Series C - II (2011), Series C - III (2011), Series C - IV (2011), Debt - III (2011), Series D (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series F (2016), Series G (2019) | 11 Series C, Series C - II (2011), Series C - III (2011), Series C - IV (2011), Debt - III (2011), Series D (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series F (2016), Series G (2019) | ||
Board Seats | Thomas Dickerson | ||||
Type | Private Equity | Investment Bank | Venture Capital | Debt & Specialty Finance | Debt & Specialty Finance |
Location | Connecticut | New Mexico | New Mexico | New York | Texas |
Exagen Acquisitions
1 Acquisition
Exagen acquired 1 company. Their latest acquisition was Cypress Bioscience - Diagnostic Business on October 08, 2010.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
10/8/2010 | Acquired Unit | 1 |
Date | 10/8/2010 |
|---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired Unit |
Sources | 1 |
Compare Exagen to Competitors

NeoDiagnostix is a cancer diagnostics company with a focus on women's health, specifically in the domain of cervical cancer detection. The company's main offering is the Cervical DNA Dtex Test, which identifies irreversible DNA damage to cervical cells as an indicator of potential cancer. This diagnostic tool is primarily utilized by healthcare providers in the medical sector. It is based in Rockville, Maryland.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
Predict to Prevent Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development of presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention

CivaTech Oncology focuses on localized radiation therapy within the medical devices sector. The company specializes in developing polymer-based low dose rate brachytherapy devices designed to treat various stages of cancer by providing targeted radiation therapy. Its products, including CivaSheet, CivaString, and CivaDerm, offer customizable solutions for radiation oncologists to deliver individualized treatment, aiming to reduce procedure time, ensure homogeneous dose distribution, and minimize patient trauma. It was founded in 2006 and is based in Durham, North Carolina.

CS-Keys is a digital marketplace for the sale of keys for the games CS:GO and Team Fortress 2. The company offers a platform for purchasing and selling virtual item keys, allowing transactions through Steam profiles and accepting payments via the Privat24 system. CS-Keys provides a service for trading these in-game keys. It was founded in 2006 and is based in Indianapolis, Indiana.

Akonni Biosystems operates in the molecular diagnostics field within the biotechnology sector. The company provides nucleic acid purification kits that use pipette-tip technology for DNA and RNA extraction, applicable for whole genome sequencing, next-generation sequencing, and polymerase chain reaction. Akonni Biosystems serves the healthcare and research sectors with its genetic testing devices and sample preparation solutions. It was founded in 2003 and is based in Fredrick, Maryland.
Loading...

